Ferring Pharma Announces EU Launch Of CORTIMENT®MMX® (budesonide) For Ulcerative Colitis

Ferring Pharma Announces EU Launch Of CORTIMENT®MMX® (budesonide) For Ulcerative Colitis
FerringFerring Pharmaceuticals recently announced the European launch of CORTIMENT® MMX® (budesonide) to address active mild and moderate ulcerative colitis (UC) -- the first and only approved oral drug for the disease. The company has also released more data concerning the CONTRIBUTE trial, which revealed that CORTIMENT®MMX® 9 mg was significantly more effective in comparison to placebo in inducing combined clinical and endoscopic remission in patients suffering from UC that continued to experience a flare up of the disease in spite of taking oral 5-ASA therapy. Data was presented at the 10th Congress of the European Crohn’s and Colitis Organisation (ECCO). David Rubin, a Professor of Medicine at the University of Chicago Medicine and lead author of the CONTRIBUTE study, said in a press release: “The data confirm the efficacy and safety of CORTIMENT®MMX® in patients experiencing an active flare of UC despite i
Subscribe or to access all post and page content.